Noopept

At Verified Peptides, we want to lead with an important classification clarification for Noopept: it is not a peptide in the sense used for the rest of this catalog, despite frequently being marketed and discussed as a "peptide-derived nootropic." Chemically, Noopept is N-phenylacetyl-L-prolylglycine ethyl ester (also known by the development code GVS-111 and, in some contexts, the name omberacetam) — a molecule that does contain an internal proline-glycine dipeptide linkage at its core, but with both ends of that dipeptide chemically capped: an N-phenylacetyl group replacing the free N-terminal amine, and an ethyl ester replacing the free C-terminal carboxylic acid. These modifications mean Noopept lacks the free amino and carboxyl termini that define a conventional peptide, and it behaves pharmacologically, legally, and chemically as a small-molecule drug rather than as a peptide.

Developed in Russia in 1996, Noopept has molecular formula C17H22N2O4, molecular weight approximately 318.37 g/mol (independently cross-checked via manual atomic-mass calculation from the formula, which matched), CAS number 157115-85-0, PubChem CID 180496. It is grouped informally with the "racetam" family of nootropic compounds due to functional similarity, though its chemical structure genuinely differs from piracetam and other true racetams, which share a 2-oxo-pyrrolidone (pyrrolidinone) ring structure that Noopept does not have.

Noopept is registered and marketed as an approved pharmaceutical drug in Russia for cognitive disorders of vascular and traumatic origin, distinguishing it from the great majority of compounds in this catalog, which lack any real-world drug approval anywhere.

This chemical strategy — building a small-molecule drug around a modified natural dipeptide core to combine a specific biological target interaction with improved pharmacokinetic properties (oral bioavailability, blood-brain barrier penetration, metabolic stability) — is a recognized medicinal chemistry approach, distinct from either the natural-hormone peptides or the fully synthetic short peptides that make up most of this catalog. Understanding Noopept's design this way helps explain why it behaves so differently in practice (oral activity, small-molecule pharmacokinetics) from true peptides of similar size, which typically require injection and have much shorter half-lives due to rapid peptidase degradation.

At Verified Peptides, we think Noopept has a genuinely more substantial human clinical evidence base than most other compounds in this catalog, and we want to describe it directly. A comparative clinical study (Neznamov and Teleshova, Neuroscience and Behavioral Physiology, 2009, PMID 19234797) treated patients with mild cognitive disorders of vascular and traumatic origin over 56 days, comparing Noopept (20 mg) against piracetam (1,200 mg). The study reported that Noopept was more effective than piracetam in improving global cognitive scores (measured via the Mini-Mental State Examination, MMSE) in patients with cerebrovascular insufficiency, and — notably — was effective in patients with post-traumatic cerebral insufficiency specifically, a population in which piracetam was reportedly not effective in the same study. This is a genuine human comparative trial with a real, specific, differentiated finding, not merely a preclinical or single-arm result.

We want to be direct about the limits of this evidence: Noopept's clinical trial literature, while real and human-based, consists primarily of Russian studies, and we are not aware of independent replication in Western clinical trial settings with the same rigor as, for example, a large multi-national randomized controlled trial. This places Noopept's evidence quality in a genuinely strong position relative to most compounds in this catalog (a real, approved drug with real comparative human trial data) while still falling short of the kind of internationally-replicated evidence base that would support broader regulatory recognition outside Russia.

No FDA, EMA, or other Western regulatory body has approved Noopept for any indication, and it is specifically not included on the FDA's list of ingredients permitted in dietary supplements in the United States — researchers should be aware that Noopept's regulatory status in the U.S. is more restrictive than for many other compounds in this catalog, reflecting its classification as an unapproved drug ingredient rather than simply an unregulated research chemical. At Verified Peptides, we sell research-grade Noopept exclusively for laboratory research, consistent with this regulatory reality.

Noopept's classification as "peptide-derived" rather than "a peptide" is a genuinely important and frequently glossed-over distinction in commercial marketing of this compound: because it retains an internal Pro-Gly dipeptide bond, some sources describe it loosely as a "dipeptide" or "peptide nootropic," but its chemically capped termini (N-phenylacetyl group and ethyl ester) mean it does not behave as a peptide chemically, is not synthesized via peptide-synthesis methods the way true peptides in this catalog are, and is regulated as a small-molecule drug ingredient rather than a peptide.

Cycloprolylglycine (CPG), Noopept's primary active metabolite, is itself an endogenous cyclic dipeptide found naturally in the human body and brain, structurally related to (though distinct from) the drug's parent compound — meaning Noopept functions, in effect, as a prodrug designed to deliver or approximate the effects of this naturally occurring molecule, a genuinely elegant piece of medicinal chemistry design reasoning even though Noopept's specific evidence base remains largely confined to Russian research.

Because Noopept is an approved drug in Russia, its regulatory classification differs meaningfully from most other compounds in this catalog in a specific, practical way: it is explicitly excluded from the FDA's list of substances permitted in U.S. dietary supplements, a more restrictive regulatory position than simply being "unapproved" or "unregulated," and researchers should understand this distinction when considering Noopept's legal status in different contexts.

The "racetam" label commonly applied to Noopept is technically imprecise: true racetams (piracetam, aniracetam, oxiracetam, and others) share a 2-oxo-pyrrolidone ring structure that Noopept's chemical structure does not contain. Noopept is grouped with this family based on functional and marketing similarity (as a cognitive-enhancing compound with a comparably favorable safety profile) rather than genuine structural relationship, a distinction worth understanding for researchers comparing Noopept directly against true racetam-class compounds.

At Verified Peptides, we require independent third-party HPLC purity testing and mass spectrometry identity confirmation for every batch of research-grade Noopept we offer, with a Certificate of Analysis (COA) available for each lot. As a small-molecule pharmaceutical compound rather than a synthesized peptide, Noopept's manufacturing and quality-control process reflects small-molecule pharmaceutical chemistry standards rather than peptide-synthesis methods.

We source exclusively from manufacturers operating under Good Manufacturing Practice (GMP)-aligned quality systems, and every lot is independently verified rather than accepted solely on a supplier's internal documentation. Researchers should always request and review the specific COA for the lot they receive, confirming purity percentage and molecular identity before use in any experimental protocol.

Noopept, as a small-molecule compound rather than a lyophilized peptide, should be stored according to the specific stability guidance provided on the Certificate of Analysis for each lot, generally at room temperature or refrigerated, protected from light and moisture.

Small-molecule compounds like Noopept are generally more chemically stable in solid form than reconstituted peptide solutions, and storage requirements tend to be less stringent than for lyophilized peptides requiring cold-chain handling after reconstitution. Researchers should nonetheless follow the specific lot documentation provided with each order rather than assuming stability based on general small-molecule chemistry principles alone.

As with any research compound, prolonged exposure to heat, direct light, or humidity can accelerate degradation and compromise the material's relevance to research applications. Following the lot-specific storage guidance provided with each order remains the most reliable way to preserve sample validity for experimental work.